SEC Form 4 · accession 0001209191-16-113575

FIVE PRIME THERAPEUTICS INC · FPRX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President, CEO and Chairman · Director

Period of report

Apr 5, 2016

Accepted (ET)

Apr 7, 2016 · 11:59 am EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001175505

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Apr 5, 2016	M	25,949	$8.49	A	366,477	D
Common Stock^F2	Apr 5, 2016	S	25,949	$43.00	D	340,528	D
Common Stock	Apr 6, 2016	M	26,852	$8.49	A	367,380	D
Common Stock^F3	Apr 6, 2016	S	26,852	$43.17	D	340,528	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F4	$8.49	Apr 5, 2016	M	25,949	D	—	Oct 19, 2021	Common Stock	25,949	96,002	D
Employee Stock Option (right to buy)^F4	$8.49	Apr 6, 2016	M	26,852	D	—	Oct 19, 2021	Common Stock	26,852	69,150	D

F1The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on November 4, 2015.
F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.00 to $43.025, inclusive. The reporting person undertakes to provide to Five Prime Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.00 to $43.44, inclusive.
F4This option is fully vested and immediately exercisable.